May 3 (Reuters) - Salix Pharmaceuticals Ltd:
* Xifaxan 550 mg (rifaximin) demonstrated acute and sustained relief of
non-constipation irritable bowel syndrome symptoms; data from target 1&2
presented at digestive disease week (ddw)
* Says treatment with Xifaxan resulted in significant improvement of global IBS
symptoms
* Says safety profiles were similar between Xifaxan 550 mg and placebo
((Bangalore Equities Newsroom; +91 80 4135 5800; within U.S. +1 646 223 8780)) (For more news, please click here) COPYRIGHT Copyright Thomson Reuters 2010. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
* Xifaxan 550 mg (rifaximin) demonstrated acute and sustained relief of
non-constipation irritable bowel syndrome symptoms; data from target 1&2
presented at digestive disease week (ddw)
* Says treatment with Xifaxan resulted in significant improvement of global IBS
symptoms
* Says safety profiles were similar between Xifaxan 550 mg and placebo
((Bangalore Equities Newsroom; +91 80 4135 5800; within U.S. +1 646 223 8780)) (For more news, please click here) COPYRIGHT Copyright Thomson Reuters 2010. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.